The price to play

The price to play

Typically, we wouldn’t spend too much time covering Medtronic earnings. The die has been cast for this struggling unit long ago. Yet things are slightly different now that Dexcom and Insulet are discussing a deal. Before we go into what today’s earnings announcement means let’s take a quick look at the numbers.

“Diabetes fiscal year 2022 revenue of $2.338 billion decreased 3% as reported and organic. Diabetes fourth quarter revenue of $597 million decreased 8% as reported and 5% organic. U.S. revenue declined in the high-twenties, given the absence of new product approvals.”

There . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.